8-K: Cassava Sciences Reports Positive Preclinical Epilepsy Data

Cassava Sciences announced positive preclinical results for simufilam in a mouse model of TSC-related epilepsy, showing attenuated seizure progression.

Summary

• Positive preclinical results were reported for simufilam in a well-accepted mouse model of tuberous sclerosis complex (TSC)-related epilepsy.
• The study was conducted in collaboration with the TSC Alliance and the TSC Preclinical Consortium, utilizing the Tsc1 conditional knockout (CKO) mouse line.
• Simufilam attenuated the progression of seizure activity in the mouse model.
• A statistically significant correlation was observed between simufilam dose and the number of seizures by the end of the study.
• Not all parameters measured in the preclinical study reached statistical significance.
• The first clinical study for simufilam in TSC-related epilepsy is expected to commence in the first half of 2026 (H1 2026).

Sentiment

Score: 7

Explanation: The sentiment is positive due to encouraging preclinical results for a new, high-need indication. However, the early stage of development and inherent risks in drug discovery temper the score, preventing it from being extremely high.

Positives

• Simufilam demonstrated a beneficial effect on seizure activity with a positive dose response in a well-accepted mouse model of TSC-related epilepsy.
• The preclinical results are consistent with prior research findings published in Science Translational Medicine, reinforcing the drug's potential.
• The study was conducted independently by PsychoGenics, Inc., a research partner of the TSC Preclinical Consortium, adding credibility to the findings.
• Simufilam shows potential as a novel, first-in-class treatment for TSC-related epilepsy, addressing a significant unmet medical need.

Negatives

• Not all parameters measured in the preclinical study reached statistical significance.
• Simufilam is an investigational product candidate and has not been approved for use in any medical indication by any regulatory authority in any jurisdiction.
• The safety, efficacy, or other desirable attributes of simufilam have not yet been established in any patient population.
• Preclinical results from earlier-stage studies may not be indicative of future results from planned later-stage or larger scale clinical trials and do not ensure regulatory approval.

Risks

• Ability to advance preclinical studies related to TSC-related epilepsy and other potential indications is uncertain.
• Ability to successfully carry out obligations under the Yale License Agreement is a factor.
• Drug discovery and development inherently involve a high degree of risk.
• Research and development activities are long, complex, and costly.
• Preclinical study results may not predict future clinical trial outcomes or guarantee regulatory approval.
• Investment in publicly traded securities carries the risk of total loss of invested money.

Future Outlook

The Company plans to continue conducting preclinical studies of simufilam relating to seizures in TSC and intends to initiate an initial proof-of-concept clinical study in H1 2026. Management believes simufilam has potential as a treatment for TSC-related epilepsy and other indications, modulating the activity of filamin A. Preclinical results are expected to be presented in an upcoming scientific conference and publication.

Management Comments

• "We are excited that this independent study bolsters previous findings in a separate animal model of focal onset epilepsy. Based on these data, we believe that simufilam could represent a new approach to addressing the persistent unmet need in the TSC community." Angélique Bordey, PhD, Senior Vice President, Neuroscience.
• "Epilepsy is considered the most prevalent and challenging manifestation of TSC. Patients urgently need more treatment options. Positive results from two independent preclinical animal studies enhance our conviction as we prepare to advance simufilam to the clinic for this new indication. We intend to initiate a proof-of-concept study of simufilam in TSC-related epilepsy in the first half of 2026." Rick Barry, President and Chief Executive Officer.

Industry Context

Tuberous Sclerosis Complex (TSC)-related epilepsy affects 80-90% of TSC patients, with two-thirds experiencing refractory epilepsy. Current therapies, including antiepileptic drugs and mTOR inhibitors, are often not fully effective and are associated with serious adverse events, indicating a significant unmet medical need for new treatment options. Simufilam's preclinical success in a well-accepted mouse model suggests a potential novel, first-in-class approach to address this persistent challenge.

Comparison to Industry Standards

• The results are consistent with findings published in Science Translational Medicine of prior research conducted with simufilam at Yale School of Medicine in another mouse model.
• The study utilized the Tsc1 conditional knockout (CKO) mouse line, a well-accepted animal model used by the TSC Alliance and TSC Preclinical Consortium to evaluate novel therapeutics for TSC-related epilepsy.
• This model is housed at PsychoGenics, Inc., a research partner of the Consortium, and was developed by Dr. Michael Wong at Washington University School of Medicine.

Stakeholder Impact

• Shareholders: Potential for increased stock value due to positive drug development news, but also high risk associated with early-stage biotech and the potential for total loss of investment.
• Patients with TSC-related epilepsy: Hope for a novel, first-in-class treatment option for a condition with significant unmet needs and a high rate of refractory cases.
• Medical Community/Researchers: New data contributing to the understanding and potential treatment of TSC-related epilepsy, potentially leading to further research and development.

Next Steps

• Present data and analyses in an upcoming scientific conference and publication.
• Initiate an initial proof-of-concept clinical study for simufilam in TSC-related epilepsy in H1 2026.
• Continue conducting preclinical studies of simufilam relating to seizures in TSC and other potential indications.

Key Dates

Recommendation

While the positive preclinical results for simufilam in TSC-related epilepsy are encouraging and open a new potential indication, the drug is still in very early stages of development. Preclinical success does not guarantee clinical efficacy or regulatory approval, and the company explicitly states the high risks involved in drug discovery, including the potential for total loss of investment. Given the significant time and capital required to advance through clinical trials and the inherent uncertainties, a 'hold' recommendation is appropriate for investors to monitor further clinical progress before making a more definitive investment decision.

Keywords

Cassava Sciences, Simufilam, TSC-related epilepsy, Tuberous Sclerosis Complex, preclinical results, biotechnology, CNS disorders, drug development, epilepsy treatment, rare genetic disorder